Advertisements

Clonate F

Quick links to important sections

Clonate F

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Clonate F

Property Description
Active Ingredients Clobetasol Propionate, Fusidic Acid
Form Topical Cream or Ointment
Pharmacological Class Potent Corticosteroid and Steroidal Antibiotic Combination
Common Use Managing severe inflammatory skin conditions with secondary infection
Origin Synthetic (Clobetasol) and Derived/Natural (Fusidic Acid)

The Identity and Classification of Clonate F

Clonate F is a specialized, prescription-only fixed-dose combination (FDC) topical medicine, typically supplied as a cream or an ointment for direct application to the skin. It is recognized as a dual-action dermatological agent because its formulation intentionally unites two distinct pharmacological classes in a single product, a strategy used for simplifying complex skin therapy. This combination structure specifically targets inflammatory dermatoses that require both potent anti-inflammatory action and control over potential bacterial involvement, distinguishing it from single-agent steroid preparations.

What is the Composition of Clonate F? (Clobetasol and Fusidic Acid)

The therapeutic strength of Clonate F is derived from its two key components: the potent, synthetic corticosteroid, Clobetasol Propionate, and the steroidal antibiotic, Fusidic Acid. Clobetasol Propionate belongs to the highest potency class of topical steroids, intended for rapid suppression of severe skin inflammation. The inclusion of this high-potency steroid is a differentiating factor, underscoring its use for severe, rather than mild, conditions. Fusidic Acid, derived from the fungus Fusidium coccineum, provides the necessary antibacterial action by inhibiting bacterial protein synthesis. The combination of corticosteroids and Fusidic Acid is utilized for skin inflammation where bacterial presence is a concern.

The General Purpose of This Dual-Action Topical

The general purpose of this topical preparation is to manage severe inflammatory dermatoses complicated by, or at high risk of, a secondary bacterial infection. The dual action ensures that the potent anti-inflammatory effects quickly alleviate discomfort, while the antibacterial activity controls the infectious element that often perpetuates complex dermatological issues. This comprehensive approach is designed to stabilize the affected skin area by addressing both primary causes concurrently.

Advertisements

What side effects are possible with Clonate F?

Possible Side Effects and Safety Information

The safety profile of Clonate F, a combination of a potent corticosteroid and an antibiotic, is primarily defined by the officially documented risks associated with high-potency topical steroids. These risks are classified by frequency, the body system affected, and the context of use.

Adverse Reaction Classifications

Official regulatory documents categorize possible adverse reactions based on how frequently they appear:

  • Common Reactions: Burning sensation, pruritus (itching), irritation at the application site, and skin atrophy (thinning of the skin).
  • Uncommon to Rare Reactions: Striae (stretch marks), telangiectasia (spider veins), folliculitis, and manifestations of allergic contact dermatitis.

Adverse effects are also categorized by the affected body system, which includes the Skin and Subcutaneous Tissue Disorders and, due to systemic absorption risk, Endocrine and Metabolism and Nutrition Disorders.

Serious Adverse Reactions and Safety Patterns

The most serious, though rare, adverse reactions documented in regulatory labeling are related to systemic absorption of the potent corticosteroid component. These include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the development of Cushing's syndrome.

Safety Domain Regulatory Note
Exposure Risk Risk of structural skin changes and systemic effects is officially documented as increasing with long-term or extensive use.
Pediatric Risk Pediatric patients are listed as having a greater risk of systemic toxicity, such as HPA-axis suppression, due to their higher skin surface area to body mass ratio.
Application Restrictions Official labeling restricts use on certain areas (e.g., face, groin) and advises against the use of occlusive dressings, as these increase systemic absorption and adverse reaction potential.

This framework establishes that while local irritation is common, the primary safety focus in official documents is on the potential for rare, serious systemic effects that are exacerbated by duration and extent of application.

Advertisements

Overdose and Emergency Response

The documented profile of an overdose for this product is associated with potential systemic absorption of the potent corticosteroid component, Clobetasol Propionate. Overuse, use over large surface areas, or prolonged application may lead to sufficient absorption to cause adverse effects related to the endocrine system. The Fusidic Acid component is generally classified as unlikely to cause overdose.

Documented Overdose Manifestations

Manifestations of systemic overdose, as described in regulatory labeling, relate directly to excessive corticosteroid exposure. These include:

  • Reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.
  • Clinical signs resembling Cushing’s syndrome.
  • Metabolic changes such as Hyperglycemia (high blood glucose) and Glucosuria (glucose in the urine).

A severe outcome that may arise is Glucocorticosteroid insufficiency upon abrupt cessation. Pediatric patients are officially noted to have an increased susceptibility to these systemic effects.

When to Seek Immediate Medical Help

Regulator-mandated guidance requires individuals to seek immediate medical attention if any manifestation of adrenal insufficiency or suspected Cushing’s syndrome is observed.

Management protocols specify that if systemic toxicity is confirmed through monitoring, the product must be gradually withdrawn, the frequency reduced, or substituted with a less potent corticosteroid. Supplemental systemic corticosteroids may be required as a supportive measure to manage established adrenal insufficiency.

Advertisements

Therapeutic Uses of Clonate F

What Clonate F Treats: Main Uses and Benefits

Clonate F is a combination topical medicine generally used for managing inflammatory skin conditions that are complicated by a bacterial infection. This dual-action approach is relevant in clinical settings that involve acute or unstable symptom patterns. The therapeutic purpose is to support symptomatic management across two domains.

The medication may support the reduction of symptoms related to inflammation, such as redness, swelling, and significant itching, in conditions characterized by heightened symptoms, including eczema, psoriasis, and dermatitis, when bacterial presence is an issue. This product is applied in addressing the symptom clusters that interfere with daily comfort. The combination helps patients cope more steadily with symptom fluctuations.

“This product may be part of symptomatic management in situations where patients experience concurrent heightened symptoms related to inflammation and bacterial presence.”


Quick Fact: Supports Management of Symptom Clusters

Advertisements

Eligibility and Restrictions for Use

This medication, a combination of a potent corticosteroid (Clobetasol) and an antibiotic (Fusidic acid), has official restrictions defining who may and may not use it.

Contraindicated Populations (Must Not Use)

Official regulatory documents contraindicate use for patients with a known hypersensitivity or allergy to Clobetasol Propionate, Fusidic acid, or any other ingredients in the preparation. It must also be avoided in the presence of untreated viral skin infections (e.g., Herpes Simplex, Varicella), fungal infections, or tubercular skin infections, as the corticosteroid component may worsen these conditions.

The drug is also contraindicated for use on certain skin conditions, specifically rosacea, acne, and perioral dermatitis.

Restricted Use and Special Caution

  • Pediatric Use: Use in children under 12 years of age is generally not recommended, or is restricted to a very short duration (e.g., five days) under strict medical supervision due to the risk of systemic absorption.
  • Pregnancy and Lactation: The medicine is not recommended for use in women who are pregnant or breastfeeding unless the potential benefits are determined by a physician to outweigh the potential risks.
  • Application Area: Use on the face, groin, or armpits is generally advised against or severely limited.
  • Organ Function: Caution is advised when considering use in patients with known liver or kidney impairment.
Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Clonate F, containing Clobetasol Propionate and Fusidic Acid, is defined by two key regulatory warnings based on the potential for systemic exposure.

Documented Exposure-Altering Interactions

Component Interacting Substance Category Official Outcome Status
Fusidic Acid HMG-CoA Reductase Inhibitors (Statins), specifically Simvastatin Increased plasma concentration of statins, leading to a high risk of muscle toxicity (rhabdomyolysis). Contraindicated
Clobetasol Propionate Strong CYP3A4 Inhibitors (e.g., ritonavir, itraconazole) Reduced clearance and increased systemic exposure of Clobetasol Propionate. Significant Risk

Regulatory documents officially contraindicate the co-administration of the Fusidic Acid component with statin medications, such as Simvastatin, due to the documented potential for severe adverse muscle effects. This constraint is supported by a mandatory timing rule that requires statin therapy to be suspended throughout the course of systemic Fusidic Acid use and for a period of seven days following the last dose, to ensure adequate clearance.

Co-administration with potent CYP3A4 inhibitors may increase the systemic concentration of the corticosteroid component, Clobetasol Propionate, as its metabolism is dependent on the CYP3A4 enzyme system. This exposure risk is officially noted to be of greater clinical relevance in pediatric patients due to factors related to systemic absorption.

Advertisements

Mechanism of Action

How Clonate F Works

The mechanism of Clonate F involves two distinct but complementary mechanistic domains: modulation of inflammatory signaling and interference with bacterial proliferation.


Modulating Inflammatory Pathway Activity

This domain describes the drug's role in regulating the Arachidonic Acid Pathway. The drug acts as an enzyme inhibitor, primarily blocking the synthesis of chemical messengers called prostaglandins. This molecular action modifies early molecular steps that normally drive vascular changes, which in turn modifies the impact of excessive mediator activity, resulting in an altered local tissue state.


Inhibiting Microbial Protein Synthesis

This domain focuses on the drug's interaction with the bacterial 50S ribosomal subunit. By binding to this structure, the drug acts as an inhibitor of protein synthesis, interfering with the microbe's ability to assemble essential proteins, halting its capacity for proliferation. This mechanism effectively engages systems where targeted pathway adjustment is required to suppress the microbial presence, leading to an observable adjustment in local physiology.

Advertisements

Dosage and Administration Information

Clonate F is a specialized, combination topical medication supplied as a cream or ointment for cutaneous administration only. There is a specific, structured protocol for its use, based on the principles governing potent topical agents.

The preparation is applied in a thin film that is gently and completely rubbed into the entire affected skin area. The standard dosing frequency is twice daily, typically scheduled for morning and evening application.

The administration protocol is defined by strict limitations due to the high potency of the corticosteroid component. The course of treatment must be confined to no more than two consecutive weeks. Furthermore, the total amount applied to the body must not exceed a maximum of 50 grams per week. Application should be discontinued as soon as the condition is controlled.

As a high-level procedural requirement, the treated area should not be covered with an occlusive dressing, such as a bandage or plastic wrap, unless specifically directed by a healthcare professional. Users are instructed to wash their hands thoroughly after application to prevent unintentional spread of the medication. Regarding specific populations, the use of this potent combination is generally not recommended for children under the age of 12.

Advertisements

Recent Clinical Evidence

Clonate F: Recent Clinical Evidence

Research evidence for this topical combination describes its clinical evaluation in patients with specific inflammatory skin conditions. This summary outlines the types of research conducted, the measures researchers used, and the areas of uncertainty, as documented in authoritative scientific sources.


Evidence for Use in Inflammatory Skin Conditions Complicated by Infection

Research has focused on conditions characterized by heightened symptom activity such as eczema and dermatitis where a secondary bacterial infection is suspected or present. Evaluation relied on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews, observing populations with moderate to severe conditions. Studies compared the combination against its components (corticosteroid alone or antibiotic alone) or against a non-active vehicle preparation. Outcomes monitored included Global Clinical Change and specific symptom clusters like redness, swelling, and itching, and how the presence of bacteria evolved during the study period. Some trials reported that the combination was associated with changes in measured outcomes when compared to the vehicle.


Long-Term Research and Follow-up Durations

The majority of clinical trials for this combination were short-term, typically involving follow-up durations of one to two weeks, reflecting research exploring acute symptom changes. Consequently, long-term effects are not fully established. There is limited information available concerning the durability of any observed changes or the risk of symptoms recurring over extended periods.


Evidence in Specific Patient Populations and Research Gaps

Research includes Adults with infected eczematous dermatosis, and the combination has also been evaluated in certain Children over the age of eight. However, data for certain groups remain insufficient, particularly for very young children or those with high comorbidity.

Limitations also include uncertainty surrounding antibiotic resistance over time. The evidence base, graded as moderate, includes findings that were mixed when comparing the product to the corticosteroid component alone. Some contextual evidence relies on studies of Fusidic Acid combined with less potent corticosteroids.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Clonate F (FAQ)


Q: How quickly should I expect to see an improvement in my skin condition after starting Clonate F?

A: Official information suggests that improvement in the skin condition may begin within a few days of starting treatment. The combination is intended to rapidly suppress severe symptoms.

Q: What are the most common side effects of using Clonate F cream?

A: Regulatory documents list common reactions that may occur at the application site. These typically include a burning sensation, itching, irritation, and skin atrophy (thinning). These effects are generally associated with the corticosteroid component.

Q: Can Clonate F cause thinning of the skin if used over an extended period?

A: Yes, official warnings confirm that the risk of skin thinning (atrophy) is documented to increase with long-term or extensive use of the potent corticosteroid component. For this reason, treatment is typically limited to short courses.

Q: Is it safe to use Clonate F on sensitive areas of the body, like the face?

A: Regulatory warnings indicate that the use of Clonate F on sensitive areas such as the face, groin, or armpits is generally not recommended or is severely limited. This restriction is due to the increased risk of systemic absorption and localized adverse effects on thinner skin.

Q: Can Clonate F be used while pregnant?

A: The medicine is generally not recommended for use in pregnant women. Official sources state that it should only be used if a physician has determined that the potential benefits clearly outweigh the potential risks.

Q: Is Clonate F safe to use if I am breastfeeding?

A: The medicine is generally not recommended for use in women who are breastfeeding. Like with pregnancy, use should only proceed if a physician has carefully assessed the benefits against any potential risks.

Q: Can using Clonate F make my skin more prone to other infections later on?

A: The corticosteroid component may worsen existing untreated viral or fungal infections, and the product is contraindicated for these conditions. The official product label does not explicitly address the long-term risk of developing other non-bacterial infections after the treatment course is finished.

Q: What is the risk of the steroid in Clonate F being absorbed into the bloodstream?

A: Because the medicine contains a potent corticosteroid, systemic absorption into the bloodstream is possible. Officially documented risks related to this absorption include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and, rarely, the development of Cushing's syndrome.

Q: Can prolonged use of Clonate F affect my body's natural hormone levels?

A: Yes, prolonged or extensive use can potentially affect hormone regulation. This risk is due to the potent corticosteroid causing Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, which can interfere with the body's natural production of stress hormones.

Q: Can Clonate F interact with medicines taken orally for other conditions?

A: Yes, the product has known interactions with oral medicines. Co-administration with statins (like simvastatin) is contraindicated due to the fusidic acid component. Separately, strong CYP3A4 inhibitors (e.g., ritonavir) may increase the systemic exposure of the clobetasol component.

Q: What is the mechanism by which Clobetasol reduces inflammation and itching?

A: Clobetasol Propionate is a very high-potency corticosteroid that works by blocking the release of specific inflammatory chemicals. This action helps to reduce symptoms like swelling, redness, and the discomfort associated with itching.

Q: Can Clonate F be used for general redness and inflammation without an active infection?

A: The official indication for this combination product is inflammatory dermatoses where a secondary bacterial infection is present or suspected. The dual-action formula is specifically designed to address both the inflammation and the microbial element concurrently.

Q: Is a slight burning sensation normal right after applying Clonate F?

A: Yes, it is common for some users to feel a burning or stinging sensation for a few minutes immediately after the cream is applied. This is an expected, local side effect related to the potent nature of the medicine.

Q: What are the signs that I might be using Clonate F for too long?

A: Signs of localized adverse effects from long-term or extensive use can include noticeable skin thinning (atrophy) and the appearance of stretch marks (striae) in the treated areas.

Q: Are there any serious, but rare, side effects of Clonate F that I should be aware of?

A: Serious, though rare, adverse reactions are primarily related to systemic absorption of the potent steroid. These include HPA axis suppression and, in rare cases, Cushing's syndrome.

Q: What happens if I accidentally get Clonate F in my eyes?

A: The product is strictly for external use on the skin. If it accidentally comes into contact with the eyes, the area should be flushed immediately with copious amounts of water.

Q: What should I do if my skin condition seems to worsen after starting Clonate F?

A: If the condition appears to worsen or fails to show improvement, professional guidance from a doctor or healthcare provider should be sought.

Q: Is there a risk of the bacteria becoming resistant to the antibiotic in Clonate F with repeated use?

A: Official information confirms that bacterial resistance has been reported with the fusidic acid component. For this reason, extended or recurrent use of the combination may increase the risk of developing antibiotic resistance.

Q: Why is Clonate F not recommended for children under 12?

A: Pediatric patients are considered to be at greater risk of systemic toxicity, such as HPA-axis suppression. This is due to their higher skin surface area-to-body mass ratio, which can lead to higher absorption of the potent corticosteroid.

Q: Why do some people experience dry skin when using Clonate F?

A: Dryness of the skin at the application site is listed in official documents as a documented side effect of the medicine.

Q: Why is Clonate F not recommended for use around the mouth?

A: The drug is contraindicated for perioral dermatitis (inflammation around the mouth). Furthermore, use on the face in general is advised against due to the high risk of side effects like skin thinning.

Q: Is it normal to feel a stinging or tingling sensation when first applying the cream?

A: Yes, stinging and tingling are reported side effects related to the local irritation caused by the medicine, and they are generally part of the same phenomena as the common burning sensation.

Q: Can Clonate F affect the color or pigmentation of my skin?

A: Yes, a side effect of the corticosteroid component is the lightening of the treated skin areas, also known as hypopigmentation.

Q: Are there specific instructions for washing the treated area before reapplying Clonate F?

A: Patient instructions advise that the affected area should be cleaned and dried well before the application of the cream.

Q: Does the strength of the ingredients in Clonate F mean it is a very potent medicine?

A: Yes, official pharmacological classifications state that the corticosteroid component, Clobetasol Propionate, is a very high-potency topical steroid. The combination is therefore considered a very potent topical medicine.

Q: Is Clonate F available in forms other than a cream, like an ointment or lotion?

A: The product is commonly supplied as a cream or an ointment. Regulatory documents generally confirm these two forms, but the availability of a specific lotion form for this combination is not universally confirmed.

Q: Is Clonate F effective for skin conditions that are purely inflammatory, without a known bacterial cause?

A: The combination is indicated for inflammatory skin conditions where a secondary bacterial infection is present or suspected. It is designed to be a dual-action agent, addressing both elements concurrently.

Q: Can Clonate F be used on the scalp for conditions like infected dermatitis?

A: The product is formulated for application to the skin. While the active components are used to treat certain inflammatory scalp conditions, use on the scalp should be limited to the affected area and guided by a healthcare professional.

Q: Why is it important to wash hands thoroughly after applying Clonate F?

A: Users are instructed to wash their hands thoroughly after applying the cream. This key step is necessary to prevent the unintentional spread of the medication to other body areas or to other people.

Advertisements

How should Clonate F be stored and disposed of?

How to Store and Dispose of Clonate F

Official regulatory guidelines strictly define the necessary conditions for storing and disposing of Clonate F (Clobetasol Propionate) to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F).
Prohibited Environment Do not refrigerate.
Packaging Keep the product in its original container and ensure the lid or tube is tightly closed to protect the contents.
Child Safety Keep out of reach of children.

Disposal Instructions

When disposing of unused or expired Clonate F, do not flush it down a toilet or pour it into a drain unless instructed to do so by a healthcare professional or regulatory program. The medication should be disposed of according to local regulatory and environmental guidelines, often by returning it to a pharmacy or using an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clonate F found in:

A-Z Index: